Risk of additional cancers in untreated and treated hairy cell leukemia patients

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 1, 2010, Pages 41-50

  Dasanu, Constantin A ^a   Alexandrescu, Doru T ^b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b Georgetown Dermatology   (United States)

Author keywords

Additional malignancies; Cladribine; Hairy cell leukemia; Immune defects; Pentostatin; Second cancers

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CYTARABINE; CYTOKINE; DAUNORUBICIN; GAMMA INTERFERON; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ALPHA; NUCLEOSIDE ANALOG; PENTOSTATIN; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD DISEASE; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CD4+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CYTOPENIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENVIRONMENTAL FACTOR; FOLLOW UP; GASTROINTESTINAL CARCINOMA; GENETIC PREDISPOSITION; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOCYTOPENIA; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SECOND CANCER; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; THYROID CANCER; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, HAIRY CELL; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PENTOSTATIN;

EID: 72849134093     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903405647     Document Type: Review

References (54)

1. Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed 2007;9(4):35
2. Jacobs RH, Vokes EE, Golomb HM. Second malignancies in hairy cell leukemia. Cancer 1985;56(6):1462-1467
3. Nielsen B, Braide I, Hasselbalch H. Evidence for an association between hairy cell leukemia and renal cell and colorectal carcinoma. Cancer 1992;70(8):2087-2090
4. Federico M, Zinzani PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002;20(3):638-646.
5. Paltiel O, Adler B, Barchana M, et al. A population-based study of hairy cell leukemia in Israel. Eur J Haematol 2006;77(5):372-377
6. Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007;99(3):215-222
7. Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood 1998;92(4):1160-1164
8. Paolini R, Poletti A, Ramazzina E, et al. Co-existence of cutaneous T-cell lymphoma and B hairy cell leukemia. Am J Hematol 2000;64(3):197-202
9. Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol 2004;75(2):107-109
10. Rimner T, Went P, Tichelli A, et al. Concomitant hairy cell and acute myeloid leukemia. Eur J Haematol 2006;76(1):86-88
11. Spielberger RT, Dickstein JI, Le Beau MM, et al. Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia. Br J Haematol 1993;83(3):519-520
12. Schön MP, Reifenberger J, Von Schmiedeberg S, et al. Multiple basal cell carcinomas associated with hairy cell leukaemia. Br J Dermatol 1999;140(1):150-153
13. Dasanu CA. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. Expert Opin Pharmacother 2008;9(9):1481-1494
14. Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 1994;8(1):92-96
15. Moss PA, Gillespie G. Clonal populations of T-cells in patients with B-cell malignancies. Leuk Lymphoma 1997;27(3-4):231-238
16. Kluin-Nelemans JC, Kester MG, Melenhorst JJ, et al. Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood 1996;87(9):3795-3802
17. van de Corput L, Falkenburg JH, Kester MG, et al. Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol 1999;93(3):256-262
18. Bigda J, Mysliwska J, Baran W, et al. Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia. Leuk Lymphoma 1993;9(4-5):371-376
19. Netea MG, Hoitink O, Kullberg BJ, et al. Defective interferon-gamma production in patients with hairy cell leukaemia. Neth J Med 2008;66(8):340-434
20. Porzsolt F, Janik R, Heil G, et al. Deficient IFN alpha production in hairy cell leukemia. Blut 1986;52(3):185-190
21. Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F, et al. Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002;116(3):595-597
22. Nakamura Y, Machii T, Tokumine Y, et al. Hairy cells from hairy cell leukemia patients presenting with pronounced polyclonal hypergammaglobulinemia secrete a factor enhancing IgG synthesis. Clin Immunol Immunopathol 1993;66(3):212-218
23. Farcet JP, Weschsler J, Wirquin V, et al. Vasculitis in hairy-cell leukemia. Arch Intern Med 1987;147(4):660-664
24. Westbrook CA, Golde DW. Autoimmune disease in hairy-cell leukaemia: clinical syndromes and treatment. Br J Haematol 1985;61(2):349-356
25. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 1995;25(2):134-142
26. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16(9):3007-3015
27. Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83(10):2906-2911
28. Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 1999;35(5-6):555-565
29. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83(12):3672-3681
30. Spiers AS. Pentostatin (2prime prime or minute-Deoxycoformycin): clinical pharmacology, role in cancer chemotherapy, and future prospects. Am J Ther 1995;2(3):196-216
31. Higman M, Vogelsang GB, Chen A. Pentostatin-pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother 2004;5(12):2605-2613
32. Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990;8(5):848-855
33. Ho AD, Männel DN, Wulf G, et al. Long-term effects of 2'-deoxycoformycin treatment on cytokine production in patients with hairy cell leukemia. Leukemia 1990;4(8):584-589
34. Schirmer M, Hilbe W, Geisen F, et al. T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine. Acta Haematol 1997;97(3):180-183
35. Lauria F, Rondelli D, Raspadori D, et al. Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur J Haematol 1994;52(1):16-20
36. Gonzalez-Stawinski GV, Yu PB, Love SD, et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Clin Immunol 2001;98:175-179
37. Van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-2259
38. Dasanu CA, Stoica-Mustafa E, Herlea V, et al. New therapies for patients with hairy cell leukemia at a glance: comprehensive review article with an illustrative case. Ann Fundeni Hosp 2005;10(3-4):75-78
39. Kraut EH. Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003;16(1):33-40
40. Pawson R, A'Hern R, Catovsky D. Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Leuk Lymphoma 1996;22(1-2):103-106
41. Troussard X, Henry Amar M, Flandrin G. Second cancer risk after interferon therapy? Blood 1994;84:3242-3244
42. Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994;15;83(10):2931-2938
43. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96(9):2981-2986
44. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003;17(1):45-51
45. Johnston JB, Eisenhauer E, Wainman N, et al. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 2000;27(2 Suppl 5):32-36
46. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17(8):2454-2460
47. Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92(6):1918-1926
48. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21(5):891-896
49. Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2- chlorodeoxyadenosine. Leukemia 2004;18(9):1476-1481
50. Larsen CR, Hansen PB, Clausen NT. Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. Am J Hematol 2002;70(1):48-50
51. Bhargava R, Barbashina V, Filippa DA, et al. Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia. Leuk Lymphoma 2004;45(5):1043-1048
52. Hassan R, Gupta M, Kern W, et al. Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature. Leuk Lymphoma 2004;45(10):2149-2152
53. Al-Fiar F, Meharchand J, Curtis J, et al. Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: case report and review of the literature. Leuk Res 1999;23(8):719-721
54. Todd SA, Morris TC, Alexander HD. Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma 2002;43(6):1343-1344